IOVA
IOVANCE BIOTHERAPEUTICS, INC.
+0.70 (+7.09%)10.57USD13.2M成交股數4.8B市值–本益比(近四季)14.7股價營收比+65.7%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 99.3M+101% | 71.4M-3% | 67.5M+15% | 60.0M+93% | 49.3M+6798% | 73.7M+15613% | 58.6M+24503% | 31.1M | 715K | 469K | 238K | – |
| 營業成本 | 43.6M | 42.5M | 38.5M | 48.9M | 42.7M | 23.1M | 31.5M | 31.4M | 7.3M | 4.3M | 2.1M | – |
| 毛利 | 55.7M+743% | 28.9M-43% | 29.0M+7% | 11.1M-4326% | 6.6M-201% | 50.6M-1407% | 27.0M-1592% | −262K | −6.5M | −3.9M | −1.8M | – |
| 毛利率 | 56.1% | 40.5% | 43.0% | 18.5% | 13.4% | 68.7% | 46.2% | -0.8% | -915.5% | -825.4% | -761.3% | – |
| 研發費用 | 58.9M | 62.5M | 75.2M | 77.9M | 76.0M | 67.3M | 67.0M | 62.1M | 79.8M | 87.5M | 86.3M | 82.7M |
| 銷售管理費用 | 39.3M | 38.9M | 34.6M | 37.6M | 43.8M | 42.0M | 39.3M | 39.6M | 31.4M | 27.0M | 21.9M | 28.1M |
| 營業利益 | −51.9M-57% | −81.0M-6% | −94.9M+7% | −114M+12% | −121M+3% | −86.6M-27% | −89.1M-19% | −102M-8% | −118M | −118M | −110M | −111M |
| 營業利益率 | -52.3% | -113.5% | -140.7% | -189.8% | -245.8% | -117.5% | -152.1% | -327.6% | -16,464.6% | -25,236.9% | -46,254.6% | – |
| 稅後淨利 | −47.3M-59% | −79.0M+1% | −91.3M+9% | −112M+15% | −116M+3% | −78.6M-31% | −83.5M-22% | −97.1M-10% | −113M | −114M | −107M | −107M |
| 淨利率 | -47.6% | -110.7% | -135.3% | -186.2% | -235.5% | -106.6% | -142.7% | -312.2% | -15,800.8% | -24,255.9% | -44,759.7% | – |
| 稀釋 EPS | -0.11-69% | -0.19-21% | – | -0.33-3% | -0.36-14% | -0.24-48% | -0.28-40% | -0.34-32% | -0.42 | -0.46 | -0.47 | -0.50 |
| 稀釋股數 | 450K | 419K | – | 335K | 323K | 290K | 303K | 285K | 266K | 246K | 224K | 214M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 111M | 197M | 158M | 132M | 172M | 116M | 164M | 229M | 134M | 268M | 230M | 543M |
| 應收帳款 | 102M | 81.8M | 66.8M | 59.9M | 70.9M | 69.3M | 55.8M | 31.6M | 234K | – | 33K | – |
| 存貨 | 55.6M | 58.4M | 51.7M | 49.8M | 65.5M | 51.5M | 38.6M | 27.9M | 17.6M | 9.2M | 9.7M | – |
| 總資產 | 916M | 926M | 905M | 907M | 967M | 910M | 991M | 964M | 870M | 852M | 757M | 825M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 179M | 204M | 203M | 209M | 199M | 200M | 218M | 196M | 190M | 178M | 179M | 158M |
| 股東權益 | 736M | 722M | 702M | 698M | 768M | 710M | 773M | 769M | 680M | 674M | 579M | 667M |
| 負債比 | 19.6% | 22.0% | 22.4% | 23.0% | 20.6% | 22.0% | 22.0% | 20.3% | 21.8% | 20.9% | 23.6% | 19.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −72.1M | – | – | −104M-15% | – | – | – | −122M | – | – | −99.8M |
| 資本支出 | – | 6.6M | – | – | 6.2M | – | – | – | 4.2M | – | – | 5.7M |
| 自由現金流 | – | −78.7M | – | – | −110M-13% | – | – | – | −126M | – | – | −105M |
| 折舊攤銷 | 9.5M | 2.8M | 9.0M | 3.4M | 2.6M | 2.3M | 3.0M | 3.0M | 3.0M | 2.9M | 2.9M | 2.8M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -110.2% | – | – | -222.8% | – | – | – | -17,685.3% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 264M
| Single Reportable | 264M | 100.0% | +60.6% |
|---|
地區2025 年度 · 264M
| 美國 | 259M | 98.3% | +60.8% |
|---|---|---|---|
| 美國以外 | 4.5M | 1.7% | +48.3% |
產品／服務2025 年度 · 264M
| Amtagvi | 220M | 83.5% | +112.4% |
|---|---|---|---|
| Proleukin | 43.5M | 16.5% | -28.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 264M | +60.6% | −391M | -148.4% | -1.09 | −336M |
| FY2024 | 164M | +13699.0% | −372M | -226.9% | -1.28 | −364M |
| FY2023 | 1.2M | – | −444M | -37,342.3% | -1.89 | −384M |
| FY2022 | – | – | −396M | –% | -2.49 | −313M |
| FY2021 | – | – | −342M | –% | -2.23 | −266M |
| FY2020 | – | – | −260M | –% | -1.88 | −252M |
| FY2019 | – | – | −198M | –% | -1.59 | −166M |
| FY2018 | 0 | – | −124M | –% | -1.27 | −102M |